{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-263491","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.373977+00:00","generated_at":"2026-05-17T00:35:40.807844+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kura Oncology Q3 net loss $74.1M; progress on ziftomenib Phase 3 trials","bullets":["Net loss of $74.1M in Q3 2025 vs $54.4M in Q3 2024; R&D spend rose to $67.9M.","Collaboration revenue of $20.8M from Kyowa Kirin partnership; no revenue in prior year.","Pro forma cash $609.7M; cash runway into 2027 supports ziftomenib program through KOMET-017 topline.","First patients dosed in KOMET-017 Phase 3 (frontline AML) and FLT3 inhibitor cohort of KOMET-007.","PDUFA target date Nov 30, 2025 for ziftomenib in R/R NPM1-m AML; two oral ASH 2025 abstracts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-263491","json":"https://secwatch.observer/filing/0001193125-25-263491.json","markdown":"https://secwatch.observer/filing/0001193125-25-263491.md","text":"https://secwatch.observer/filing/0001193125-25-263491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/0001193125-25-263491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:35:40.807844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}